Evidence map›Paper›PMID 40960860›Full record

ArticleThe Biochemical journal2025

De novo talin-1 variant L353F connects multifaceted clinical symptoms to alterations in talin-1 function.

Muktesh Athale, Neil Ball, Latifeh Azizi, Irene Valenzuela, Marta Codina, Andrea Martin-Nalda, Vasyl V Mykuliak, Rolle Rahikainen, Benjamin T Goult, Paula Turkki and 1 more

Abstract readCase Reports
In one paragraph

Article in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Muktesh AthaleFaculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.ORCID 0009-0005-0827-0800
Neil BallDepartment of Biochemistry, Cell & Systems Biology, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K.ORCID 0000-0001-7165-6363
Latifeh AziziFaculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.ORCID 0000-0001-7026-6507
Irene ValenzuelaClinical and Molecular Genetics Area, Vall d'Hebron Hospital, Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.ORCID 0000-0003-2350-6058
Marta CodinaClinical and Molecular Genetics Area, Vall d'Hebron Hospital, Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Andrea Martin-NaldaPediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Vasyl V MykuliakFaculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.ORCID 0000-0002-2522-9907
Rolle RahikainenFaculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.ORCID 0000-0003-1265-862X
Benjamin T GoultDepartment of Biochemistry, Cell & Systems Biology, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K.ORCID 0000-0002-3438-2807
Paula TurkkiFaculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.ORCID 0000-0002-5969-4807
Vesa P HytönenFaculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.ORCID 0000-0002-9357-1480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Talin-1 is a central integrin adapter protein connecting cytoplasmic domains of integrins to the cytoskeleton. These talin-1-mediated mechanical linkages are crucial for cellular functions such as cell movement and connections with other cells. Here, we report a patient carrying a missense variant, L353F, in the talin-1 head which is associated with a complex set of symptoms, including skin lesions, blood cell abnormalities, and congenital cataracts. We conducted structural and cellular characterization of this variant. Recombinant talin-1 F2F3 fragment with the corresponding mutation showed a decrease in thermal stability and decreased solubility. Reconstitution of talin-deficient cells with L353F talin-1 revealed decreased cell migration velocity, defects in wound healing capacity, and changes in recruitment of the focal adhesion complex protein paxillin. We also observed decreased levels of activated integrin in cells expressing the talin-1 variant, while integrin-binding affinity was preserved as determined biochemically. These observations suggest that changes in integrin adhesion complex dynamics reflect cellular processes and the multifaceted patient phenotype.

Indexed as

Mutation, MissenseTalinCell MovementHumansTalinTLN1 protein, humanfocal adhesion kinasemissense mutationpaxillinskin diseaseTLN1wound healing

Identifiers

PMID40960860
PMCPMC12599238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.